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Abstract  
HNF4A mutations cause increased birth weight, transient neonatal hypoglycaemia and 
maturity onset diabetes of the young (MODY). The most frequently reported HNF4A 
mutation is p.R114W (previously p.R127W) but functional studies have shown inconsistent 
results, there is lack of co-segregation in some pedigrees and an unexpectedly high frequency 
in public variant databases. We confirm that p.R114W is a pathogenic mutation with an odds 
ratio of 30.4 (95% CI: 9.79 – 125, P=2x10
-21
) for diabetes in our MODY cohort compared to 
controls. p.R114W heterozygotes do not have the increased birth weight of patients with 
other HNF4A mutations (3476g vs. 4147g, P=0.0004) and fewer patients responded to 
sulfonylurea treatment (48% vs. 73%, P=0.038). p.R114W has reduced penetrance; only 54% 
of heterozygotes developed diabetes by age 30 compared to 71% for other HNF4A mutations. 
We re-define p.R114W as a pathogenic mutation causing a distinct clinical subtype of 
HNF4A MODY with reduced penetrance, reduced sensitivity to sulfonylurea treatment and 
no effect on birth weight. This has implications for diabetes treatment, management of 
pregnancy and predictive testing of at-risk relatives. The increasing availability of large-scale 
sequence data is likely to reveal similar examples of rare, low-penetrance MODY mutations.  
 
Introduction 
Heterozygous loss of function HNF4A mutations cause maturity onset diabetes of the young 
(MODY)[1]. HNF4A is a transcription factor important in the function of the pancreatic β-
cell. Patients with HNF4A mutations present with a common phenotype of increased birth 
weight (median increase of 790g) and occasional neonatal hypoglycaemia (15%)[2]. HNF4A 
MODY patients are typically sulfonylurea sensitive and a genetic diagnosis is important 
because it determines the best treatment. Mutations in HNF4A account for 10% of genetically 
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confirmed MODY cases[3]. The most commonly reported HNF4A mutation is p.R114W 
(NM_175914.4:c.340C>T p.Arg114Trp, rs137853336, previously described as p.R127W[4]). 
In our MODY cohort it accounts for 30/176 (17.1%) HNF4A cases, while in two Italian 
cohorts 5/6(83.3%) HNF4A cases were caused by p.R114W [5, 6]. 
Several pieces of evidence made us question whether p.R114W truly causes MODY. 
p.R114W is present in the ExAC database[7] in 7/32198 European (non-Finnish) samples 
when we would only expect 0.35 HNF4A MODY cases based on a population frequency of 
MODY of 108 per million and HNF4A mutations only accounting for 10% of MODY 
cases[3]. Another source of doubt over the pathogenicity of p.R114W comes from published 
families. The original p.R114W family[4] contains two phenocopies diagnosed at 11 and 36 
years of age and a p.R114W heterozygote who was not diagnosed with diabetes until age 90. 
Shanker et. al[8] presented the case of a digenic pedigree of HNF1A p.G292fs and p.R114W; 
however p.R114W was inherited from a clinically unaffected mother (at age 46) who did not 
have a dominant family history of diabetes. There is also controversy over the functional 
effect of the mutation. Navas et. al[9] assessed the transcriptional transactivation of p.R114W 
to be the same as wild type, concluding that it was a polymorphism. Two later studies 
suggested a 30% and 50% reduction in activity compared to wild type [10, 11].  
In this study we show that p.R114W is a pathogenic mutation causing MODY-like diabetes, 
but with reduced penetrance and a distinct clinical phenotype. 
 
Methods 
MODY cohort 
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Between 1996 and 2016, 2289 probands with a clinical suspicion of MODY were referred for 
genetic testing to the Molecular Genetics Laboratory at the Royal Devon and Exeter Hospital. 
Clinical information was provided on a standardised referral form by the clinician at the time 
of referral for genetic testing, this included a question on sulfonylurea sensitivity. The latest 
version of the referral form can be found at http://diabetesgenes.org/content/mody. 
30 probands and 51 family members with p.R114W were identified by Sanger sequencing of 
HNF4A.  One additional proband was heterozygous for p.R114W and a pathogenic HNF1A 
mutation, p.R159Q; they were excluded from analysis to avoid confounding results. 100 
probands and 224 family members with other pathogenic HNF4A mutations were identified. 
Pedigrees demonstrating co-inheritance were defined as those where p.R114W was inherited 
from a mutation positive parent with diabetes. 
Variants were classified as pathogenic if they were nonsense, frameshift or essential splice 
site mutations. Missense mutations had to be reported in the literature as pathogenic in three 
or more families. 
Type 2 diabetes cases and control samples 
The type 2 diabetes cases (N=9185) and controls (N=12890) were all of white European 
ancestry and came from three sources. Clinical characteristics are provided in Supplementary 
Table 1.  
Of these, 6763 cases and 7073 controls were from the Genetics of Diabetes Audit and 
Research in Tayside Scotland (GoDARTS), described previously[12].  
2100 were cases from the Diabetes UK Warren 2 repository[13] and 1519 controls were from 
the UK Blood Services Collection of Common Controls. The cases include probands from the 
Warren 2 sib-pair, trios and duos resources and additional cases diagnosed between 35 and 65 
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years of age, described previously[14]. The controls were part of the Wellcome Trust Case 
Control Consortium, described previously[15].  
770 cases and 4849 controls came from the Exeter Ten Thousand study (EXTEND) 
(www.exeter10000.org), which recruited volunteers over the age of 18 years living within 
25 miles of Exeter, UK, and the Exeter Family Study of Child Health (EFSOCH), described 
previously[16]. 
Genotyping 
Genotyping p.R114W in the type 2 diabetes case control study samples was performed by 
LGC genomics (Middlesex, UK) using a KASP assay. We included 5 positive control 
samples to ensure adequate genotype clustering. The genotyping success rate was >95% in all 
cohorts and there were no discrepancies amongst 758 duplicate pairs.  
Haplotype analysis 
The haplotype context of p.R114W were assessed in a subset of 34 patients by genotyping 
SNPs flanking the mutation; based on methods described previously[17]. See Supplementary 
Table 2 for list of SNPs.  
Computational analyses 
Birth weights were corrected for gestational age using the 1990 British child growth 
reference data[18]. Statistical analysis was performed in Stata® (version 14); tests specified 
in text. T-tests assumed unequal variances. The Kaplan-Meier plot records the proportion of 
heterozygotes who are diabetic at each age where data is available, for those patients who did 
not develop diabetes age was censored at age of referral.  The effect of p.R114W was 
assessed using in silico tools run using Annovar[19] and Alamut (Rouen, France). 
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 Results: 
p.R114W is enriched in MODY cohort compared to controls and patients with type 2 
diabetes 
In our MODY cohort we identified 30/2289 (1.3%) probands with p.R114W of which 
26/1696 (1.5%) are white European. This compares to 4/12890 (0.03%) controls (OR  49.4, 
95% CI: 17.1 - 194, P=3.7x10
-37
). p.R114W is present in 7/32198 (0.02%) European (non-
Finnish) samples in ExAC[7], comparable to our controls (OR 1.43, 95% CI: 0.301- 5.62, 
P=0.52). To assess if p.R114W predisposes to type 2 diabetes rather than MODY we 
genotyped 9185 individuals with type 2 diabetes. There are 26/1696 p.R114W heterozygotes 
amongst the white Europeans in our MODY cohort compared to 9/9185 (0.1%) patients with 
type 2 diabetes which gives an odds ratio of 15.6 (95% CI: 7.08 - 38.0, P=2x10
-21
). The odds 
ratio of prevalence in the type 2 diabetes samples versus controls is 3.16 (95% CI: 0.88 - 
14.0, P=0.05; Supplementary Table 3). Overall these results suggest that p.R114W 
predominantly predisposes to MODY-like rather than type 2 diabetes. Co-inheritance of 
p.R114W and diabetes is not consistent with high penetrance  
Co-inheritance studies were possible in 14/30 pedigrees, in which p.R114W showed co-
inheritance with diabetes in 10/14 (Supplementary Figure 1). In the 4 families where 
p.R114W did not demonstrate co-inheritance with diabetes there are 4 non-diabetic p.R114W 
heterozygotes aged 36-53. 82% of individuals heterozygous for other HNF4A mutations are 
expected to be diabetic by age 36 (Figure 1A). In addition to the previously reported 
p.R114W/HNF1A digenic pedigree[8] we identified a proband with p.R114W and a 
pathogenic HNF1A mutation, p.R159Q. While the majority of families tested demonstrate co-
inheritance consistent with a pathogenic mutation, the presence of multiple non-diabetic 
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family members with p.R114W aged >30 years is not consistent with the high penetrance 
typical of HNF4A mutations. 46% of p.R114W heterozygotes were not diabetic at age 30 
compared to 29% for other HNF4A mutations (Figure 1A). Patients with p.R114W are 34.2% 
less likely to develop diabetes compared to other HNF4A mutations across the age range in 
our cohort (stcox, P=0.013). 
Multiple independent origins of the p.R114W mutation  
Identifying a variant on multiple haplotype backgrounds provides evidence for pathogenicity 
by excluding the presence of a separate, unobserved pathogenic mutation on the same 
haplotype. Analysis of flanking SNPs suggests that p.R114W arose on at least two haplotype 
backgrounds (maximum shared haplotype <368kb; Supplementary Table 2).  
p.R114W heterozygotes have a distinct phenotype compared to patients with other 
HNF4A mutations  
Raised birth weight is a clinically important feature of HNF4A MODY as it impacts on 
pregnancy management[2]. p.R114W heterozygotes show no increase in birth weight 
compared to the general population (mean SDS -0.032, 95% CI:-0.67 - 0.61) and a significant 
decrease compared to patients with other HNF4A mutations (t-test, P=0.0003) (Table 1). The 
age of diagnosis of diabetes is later, at a median of 34 years of age compared to 24 years for 
other HNF4A mutations (t-test, P=0.018), which is consistent with p.R114W having a lower 
penetrance. Clinician reported sensitivity to sulfonylureas is also lower than for other HNF4A 
mutations (47.6% compared to 72.9%, t-test, P=0.038). An analysis of just the white 
European subset gave similar results (Supplementary Table 4). 
 
Discussion: 
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p.R114W is a pathogenic mutation causing MODY-like diabetes, but with reduced 
penetrance  
p.R114W is enriched in our MODY cohort and demonstrates partial co-inheritance with 
diabetes. However individuals with the mutation do not always present with the disease – the 
mutation therefore has reduced penetrance. It is possible that secondary genetic or 
environmental factors may be necessary to cause disease. p.R114W affects a conserved base 
according to its GERP score, is a conserved amino acid (down to Fruit fly) and is predicted to 
be deleterious by in silico tools including SIFT and Polyphen (Supplementary Table 5). This 
supports the case that it is a pathogenic variant.  
There is some evidence that p.R114W is a hypomorphic mutation with transactivation 
activity reduced but not absent in vitro[10, 11]. p.R114W is in the DNA binding domain of 
HNF4A. Chandra et al. demonstrated that it had reduced DNA binding affinity compared to 
wild type but with a smaller effect than that observed for other HNF4A mutations[20]. The 
previously reported HNF4A p.R76W is also in the DNA binding domain and causes renal 
features in addition to the classical HNF4A symptoms [24]. This suggests that the difference 
in DNA binding affinity may be the cause of the atypical sets of phenotypes presented by 
these two mutations, by dictating which target genes the HNF4A transcription factor is able to 
interact with.  
Other hypomorphic rare MODY gene variants include the HNF1A p.G319S 
missense/splicing variant in the Oji Cree[21, 22] and the hypomorphic p.E508K variant in 
Latinos [23]. There is also some evidence that p.T130I is a low-frequency variant 
predisposing to type 2 diabetes in Europeans[24]. These variants are associated with an 
increased risk of type 2 diabetes whereas p.R114W appears to predominantly cause MODY-
like diabetes in both Caucasian and Japanese pedigrees.  
Page 8 of 36Diabetes
p.R114W has no effect on birth weight  
p.R114W heterozygotes have a distinct clinical presentation of HNF4A MODY-like diabetes 
with normal birth weight. The p.R76W HNF4A mutation causes a unique phenotype of renal 
Fanconi syndrome in addition to the common HNF4A diabetic phenotype[25], but still causes 
increased birth weight. p.R114W appears to be having an effect in the adult but not the fetus. 
One speculative mechanism for this would be a lower threshold of HNF4A activity required 
in the fetus for healthy function.  
Reclassifying the clinical features of p.R114W will impact patient treatment and family 
management 
p.R114W has a distinct profile of clinical features. This means that specific recommendations 
for patient management are required. In contrast to offspring who inherit other HNF4A 
mutations, fetal inheritance of p.R114W will not confer a high risk of macrosomia. Whilst 
sulfonylurea treatment is successful for some patients, overall response is lower compared to 
patients with other HNF4A mutations. The reduced penetrance of this mutation is important 
for genetic counselling of at-risk relatives undergoing predictive tests since the chance of 
presenting with diabetes is no longer based simply on the odds of inheriting the mutation; not 
all heterozygotes will develop diabetes and those that do are likely to have a later onset.  
Ascertainment bias affects estimates of penetrance  
This study is based on the largest cohort of families with p.R114W included in a single study, 
giving us the clearest view of the characteristics of the mutation. However, there is a risk of 
ascertainment bias due to the referral criteria for MODY genetic testing. Probands were 
selected based on diabetic symptoms, age of diagnosis and, importantly, a family history of 
diabetes. This means we are at risk of overestimating the penetrance of p.R114W. However 
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this will be the case for all MODY genes, making comparisons of penetrance fair. 
Ascertainment bias is one of the reasons it is hard to establish accurate estimates of 
penetrance for rare diseases. Publically available sequencing data (such as ExAC[7] and the 
1000 genomes project[26]) can be used as controls to help generate unbiased estimates of 
penetrance. However in the case of MODY, using ExAC as a control has the limitation that it 
contains some individuals with type 2 diabetes, a subset of these could have misdiagnosed 
MODY. Removing these would only strengthen our conclusions.    
Identifying p.R114W on two distinct haplotypes demonstrates that while it is possible for 
there to be a founder effect in Europeans, it cannot explain all cases of p.R114W. The fact 
that the majority of p.R114W patients are European could also be attributed to ascertainment 
bias as the majority of our cohort were recruited in the UK.  
The pathogenicity of MODY mutations found in ExAC should be questioned  
The estimated prevalence of MODY in the United Kingdom is 108 per million population[3]. 
The most frequently reported individual MODY mutation accounts for 15% of MODY 
cases[27]. Based on this frequency we would expect to see the commonest individual MODY 
mutation in ExAC European (non-Finnish) at a frequency of only 0.52, thus any MODY 
mutation seen multiple times in ExAC is unexpectedly common and should have its 
pathogenicity and penetrance re-evaluated.  
Conclusion 
The most frequently reported HNF4A mutation, p.R114W, causes a distinct clinical 
phenotype of monogenic diabetes with reduced penetrance, no increase in birth weight and a 
lower likelihood of response to sulfonylureas. The increasing availability of large-scale 
sequence data is likely to reveal similar examples of rare, low-penetrance MODY mutations. 
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Table 1 
Characteristics of carriers of p.R114W compared to carriers of other pathogenic HNF4A 
mutations. 
 p.R114W 
mutation 
Other 
pathogenic 
HNF4A 
mutations 
P  
Probands 30 100 N/A 
Heterozygous family members  27 134 N/A 
Birth weight corrected to 40 weeks 
gestation (g) (Mean (95% CI)) 
3476 (3160,3792) 
(n=23) 
4147 (3985,4309) 
(n=84) 
0.0004 *
 
 
Standard deviation scores of birth 
weight (Mean (95% CI)) 
-0.032 (-
0.67,0.61) (n=23) 
1.36 (1.03,1.68) 
(n=84) 
0.0003 *
 
 
Birth weight corrected to 40 weeks 
gestation >4000g 
5 (n=23) 45 (n=84) 0.009 †  
Age of diagnosis of diabetes in 
probands (years) (Median (Q1,Q3)) 
21 (15,32) (n=30) 
21 (16,28) (n= 
96) 
0.63 *
 
 
Age of diagnosis of diabetes in family 
members (years) (Median (Q1,Q3)) 
34 (20,50) (n=21) 24 (16,34) (n=95) 
0.018 *
 
 
Duration of diabetes (years) (Median 
(Q1,Q3)) 
5 (0,14.5) (n=51) 7 (1,19) (n=191) 
0.025 *
 
 
Initial treatment of diabetic patients 
(Diet/OHA/Ins) 
10/19/16 (n=45) 47/50/59 (n=156) N/A 
Diabetic patients treated with 
sulfonylureas at some time during 
diabetes  
21 70 N/A 
Patients reported as being 
sulfonylurea sensitive 
10 (47.6%) 51 (72.9%) 0.038 †  
BMI of diabetic patients (Median 
(Q1,Q3)) 
22.65 
(22.975,29.2) 
(n=40) 
23.9 (21.945,27) 
(n=128) 
0.97 *
 
 
Median HbA1c of diabetic patients 
(IFCC & DCCT) 
65.0mmol/mol 
8.1% (n=31) 
57.4mmol/mol 
7.4% (n=151) 
0.97 *
 
 
*t-test  †fisher’s exact test 
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Figure 1  
Kaplan-Meier plot comparing the proportion of p.R114W heterozygotes that are diabetic to 
patients with other pathogenic HNF4A mutations (at each age where data is available). Panel 
A includes all probands and family members – the hazard ratio for diabetes is 0.659 
(P=0.013) comparing p.R114W heterozygotes to patients with other HNF4A mutations. Panel 
B includes only family members to remove the effect of ascertainment bias in the probands – 
the hazard ratio for diabetes is 0.553 (P=0.013) comparing p.R114W heterozygotes to 
patients with other HNF4A mutations. 
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Study total cases total controls cases age at diagnosis in yrs (SD) cases treatment (Diet/OHA/Insulin %)
GoDARTS 6763 7073 59.2 (11.8) 24/56/20
EXTEND/EFS 770 4849 60 (11.1) 14/54/32
W2/NBS 2100 1519 50.0 (9.2) 12/65/22
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cases age at study in yrs (SD) controls age at study in yrs (SD) cases bmi in kg/m2 (SD)
66.0 (11.3) 60.8 (13.1) 31.4 (6.1)
67.8 (9.9) 45.0 (15.9) 30.7 (5.6)
58.3 (10.2) N/A 31.3 (6.4)
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control bmi in kg/m2 (SD)
27.2 (4.6)
26.0 (4.4)
N/A
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Variant Name: rs6124140 rs6029393 rs909776 rs926293 rs6065647
Chromosome name: 20 20 20 20 20
Chromosome position start (bp): 39334539 40866127 42099246 43315567 43754256
Chromosome position end (bp): 39334539 40866127 42099246 43315567 43754256
FamilyID
0047JB01 ?? AG GG AG CG
0047JB02 AA GG ?? AA CG
0047JB05 AA GG GG AA CG
0741AR02 AC AG AA AA CC
0741AR05 AC AG AG AA CG
0741AR07 AC AG AA AA CC
0912BP01 AC AA AG AG CG
0998LS02 AC AG AA AG CC
1658HT01 AC AA AA AA CC
1658HT02 AC AG AG AA CC
2691FW01 CC AG AA AA CG
2967AB01 AA GG AA AG CG
2967AB04 AA AG AG AG CG
3344NH01 AC AG AA AA CG
4697CH03 AA AG AA AA CG
4697CH04 AA AG AG AA CG
4940CB01 AC AG AG AG CC
4940CB02 AC AG AA AG CG
4940CB03 AA AG AA GG CC
4940CB04 AC AA AG AG CC
4996KV01 AC GG AG GG CG
4996KV03 AC GG GG AG CG
5112NF01 CC GG AG AA CC
5295PS02 CC AG AG AG CG
5625AC01 AC AG AA AG CG
6432AM01 AA AG AG AA GG
6432AM02 AC AG AG AG GG
6668CM01 AA AA AG AG CG
8134CY04 CC AA AG AA CC
8134CY06 CC AG GG AG CC
8426CC01 ?? AG AA AA CG
8426CC02 CC AG AA AA CG
8426CC03 CC GG AG AA CG
8844PD01 AC AA AG AG CC
Red cells indicate where there is evidence for p.R114W occurring on a different haplotype background because of opposite homozygous genotypes flanking p.R114W
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rs6031225 rs6093923 rs2143606 p.R114W rs6031601 rs2425641 rs2299691 rs4810439 rs2144649
20 20 20 20 20 20 20 20 20
43919190 44061352 44209910 43042354 44429180 44512435 44643697 44749229 44960678
43919190 44061352 44209910 43042354 44429180 44512435 44643697 44749229 44960678
AA AG AG CT AC TT GG GG AC
AA ?? AG CT AC CT GG GG AC
AA AG AG CT CC CT GT CG CC
AC AA GG CT AC TT GT CG AA
AA AA GG CT CC TT GT CG AC
AC AA GG CT AC TT ?? CG AA
AA AG AG CT AC TT GG CG AC
AA AA AG CT AC CT GT CG AC
AC AG AG CT AC TT GG CG AA
AA AA GG CT AC TT GG CC AC
CC AA AG CT CC CT GG CG AC
AC AG GG CT CC TT GG GG AC
AC AG AG CT AC CT GG GG CC
AC GG AG CT CC CT GT GG AC
AA AA AG CT CC TT GG CG AC
AC AG AG CT AC CT GG GG CC
AA AG AG CT AC CT GG CG CC
AA AG GG CT CC TT GG GG CC
AA AG AG CT AC CT GG CG CC
AC AG GG CT AC CT GG CG CC
CC AA AG CT AA CT GT CG CC
AC AG AG CT AC TT GG CG CC
AC AA GG CT AC TT GT GG AC
CC GG AG CT CC TT GG CG AC
AA GG AG CT CC CT GG CG CC
AC GG GG CT AC TT GT GG AC
AA AG AG CT CC TT GT GG AA
AA AA AG CT CC TT GT CG AC
AC AA GG CT CC TT GT GG CC
AA AA GG CT AC CT GG CG CC
AC AA AG CT AC CT GG GG AC
AC AA AG CT CC TT GT GG AC
AA AA AG CT AC TT GT GG CC
AA AG GG CT CC CT GG CC AC
Red cells indicate where there is evidence for p.R114W occurring on a different haplotype background because of opposite homozygous genotypes flanking p.R114W
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rs3529 rs11086175rs914870 rs2057077
20 20 20 20
45345218 46508723 47751492 49407099
45345218 46508723 47751492 49407099
AA CT TT CT
AA CT CT CT
AG TT TT CT
AG CT CT CT
AA CT CT CT
AG CT CT CT
AA CT TT CT
AA CT TT CT
AG CC CT CT
AG CC CT CT
AA CT CT TT
AG TT TT TT
AA TT TT CT
AG CC CC TT
GG CT CT CT
GG CC CT CT
AG CC CC CC
AA CC CC CC
AG CC CC CC
AA CC CC CT
AG CC CC CT
GG TT CC CC
AG TT CC TT
GG CT CT TT
AA TT CT CT
AG CT CT CT
AG CC CT TT
AA TT CC CT
AA CT CT CC
AG CT CT CC
GG CC CC CC
AG CT CC CT
AG CC CC CC
AA CT TT CC
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Study cases CC/CT/TT controls CC/CT/TT OR
GoDARTS 0/3/6446 0/1/6702 3.119143655
EXTEND/EFS 0/2/750 0/1/4712 12.56533333
W2/NBS 0/4/1955 0/2/1476 1.509974425
Combined 0/9/9151 0/4/12890 3.169
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Fishers exact P
0.366
0.052
0.705
0.051
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Data from white European subset 
 R114W mutation Other pathogenic 
HNF4A mutations 
P  
Probands 26 87 N/A 
Heterozygous family members  24 123 N/A 
Birth weight corrected to 40 weeks 
gestation (g) (Mean (95% CI)) 
3545 (3189,3900) 
(n=19) 
 4143(3813,4473) 
(n=74) 
0.0036
 
*
 
Standard deviation scores of birth weight 
(Mean (95% CI)) 
0.084 (-0.64,0.81) 
(n=19) 
1.35 (0.69,2.01) 
(n=74) 
0.0028
 
*
 
Birth weight corrected to 40 weeks 
gestation >4000g 
 5 (n=19)  40 (n=74) 0.040
 
† 
Age of diagnosis of diabetes in probands 
(years) (Median (Q1,Q3)) 
 21.5 (17.25,32) 
(n=26) 
 21(17,28) (n=85) 0.49
 
*
 
Age of diagnosis of diabetes in family 
members (years) (Median (Q1,Q3)) 
 31.5 (20.5,45.25) 
(n=18) 
 24 (16,34) (n=89) 0.082
 
*
 
Duration of diabetes (years) (Median 
(Q1,Q3)) 
 6 (0,16) (n=44) 8 (1.25,19) (n=174) 0.12
 
*
 
Initial treatment of diabetic patients 
(None/OHA/Ins) 
11/18/13 (n=42) 42/48/52 (n=142) N/A 
Diabetic patients treated with 
sulfonylureas at some time during 
diabetes  
20 57 N/A 
Patients reported as being sulfonylurea 
sensitive 
8(40%) (n=20)  51(89.5%) (n=57) 
7x10
-6 
†
 
 
BMI of diabetic patients (Median 
(Q1,Q3)) 
 25.85 (23.0,29.8) 
(n=36) 
 23.9 (22.0,27) 
(n=116) 
0.037
 
*
 
Median HbA1c of diabetic patients (IFCC 
& DCCT) 
9.7mmol/mol 
7.7% (n=27) 
9.5mmol/mol 
7.6% (n=138) 
0.15
 
*
 
*t-test  †fisher’s exact test 
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SIFT_score SIFT_pred Polyphen2_HDIV_scorePolyphen2_HDIV_predPolyphen2_HVAR_scorePolyphen2_HVAR_predLRT_score LRT_pred MutationTaster_score
0 D 1 D 0.988 D 0 D 1
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MutationTaster_predMutationAssessor_scoreMutationAssessor_predFATHMM_scoreFATHMM_predRa ialSVM_scoreRadialSVM_predLR_score LR_pred
D 3.085 M -3.53 D 1.018 D 0.912 D
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VEST3_scoreCADD_raw CADD_phredGERP++_RSVEP impactnearestSSChangelocalSpliceEffectconservedDistSpecies
0.95 3.884 19.74 3.06 Moderate 0 none Fruitfly 
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Supplementary Figure 1 
Pedigrees of the thirty HNF4A R114W families.  Family ID numbers are indicated above each pedigree. Arrows indicate the proband, squares represent 
males and circles are females.  Black symbols indicate patients affected with diabetes.  MN indicates individual heterozygous for R114W, NN indicates no 
mutation.  Information provided underneath genotype in descending order is: current age (years), age of diagnosis of diabetes (years), initial treatment, 
BMI (kg/m
2
) and birthweight (g) adjusted for gestational age.   A) 10 families where R114W co-segregated with diabetes; B) 4 families where R114W did not 
co-segregate with diabetes; C) 16 families where co-segregation was not possible to assess.  Co-segregating pedigrees were defined as those where R114W 
was inherited from a mutation positive parent with diabetes. In family 5295PS the proband was positive for GAD antibodies and had low urine C-peptide, 
consistent with a diagnosis of type 1 diabetes. Family 9862TT contains 3 phenocopies; we attribute these to type 2 diabetes due to the older age of 
diagnosis (median 40 years of age) and high BMI (34, 37 and 43). 
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